Results 81 to 90 of about 15,263 (254)
Case Report: Rare Dupilumab-Associated Pulmonary and Extrapulmonary Tuberculosis [PDF]
Weiyan Xu,1 Jianfeng Zhong2 1Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, People’s Republic of China; 2Department of Infectious Disease, Huzhou Key Laboratory of Precision Medicine Research and Translation ...
Zhong J
core
JEADV Clinical Practice, EarlyView.ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva +17 more
wiley +1 more source
Facial erythema after the treatment of dupilumab in SLE patient
Allergy, Asthma & Clinical Immunology, 2020 Background Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers.
Dong Hyek Jang +5 more
doaj +1 more source
Pediatric Investigation, EarlyView.This review synthesizes epidemiological evidence linking atopic dermatitis to attention‐deficit/hyperactivity disorder in children, proposes an “inflammation‐itch‐neurobehavioral axis” integrating sleep disruption, neuroendocrine dysregulation, and emerging neuro‐immune circuits, and outlines multidisciplinary management strategies targeting both skin ...
Qingyang Zhao +11 more
wiley +1 more source
, 2020 Jean Kim,1,2 Robert Naclerio1 1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Department of Medicine: Allergy and Clinical Immunology, Johns Hopkins University School of Medicine ...
Naclerio R, Kim J
core
Phytotherapy Research, EarlyView.ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit +5 more
wiley +1 more source
World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou +4 more
wiley +1 more source
Dupilumab in the management of moderate-to-severe asthma: the data so far
, 2017 Pilar Barranco,1 Elsa Phillips-Angles,2 Javier Dominguez-Ortega,1 Santiago Quirce1 1Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; 2Department of ...
Javier Dominguez-Ortega +7 more
core +1 more source
Dupilumab in the treatment of severe non-control broncial asthma — economic aspects
Качественная клиническая практика, 2019 Severe non-control Bronchial Asthma (BA) is a sufficient social problem with decreasing of quality of life, high index of disability and death. New biological drug — dupilumab — would improve the situation.Materials and methods.
A. S. Salasyuk +2 more
doaj +1 more source
World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) impacts patients' concentration, ability to work, and overall quality of life. Current treatment options include topical and oral medications, and surgery. Recent evidence supports the efficacy of biologics in improving symptoms and quality of life.
Baharudin Abdullah +19 more
wiley +1 more source